Compare DOMO & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DOMO | TECX |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 359.0M |
| IPO Year | 2018 | 2018 |
| Metric | DOMO | TECX |
|---|---|---|
| Price | $8.64 | $18.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $14.38 | ★ $81.20 |
| AVG Volume (30 Days) | ★ 952.0K | 285.5K |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $318,002,000.00 | N/A |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.01 | $13.70 |
| 52 Week High | $18.49 | $61.07 |
| Indicator | DOMO | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 28.24 | 45.99 |
| Support Level | $8.43 | $17.79 |
| Resistance Level | $9.27 | $19.12 |
| Average True Range (ATR) | 0.57 | 1.42 |
| MACD | -0.05 | -0.31 |
| Stochastic Oscillator | 7.33 | 16.97 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.